Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S026 - Psoriasis

Saturday, February 17; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize and manage the comorbidities and health risk factors in psoriasis patients
  • Treat nail and genital psoriasis and recognize psoriatic arthritis
  • Manage psoriasis in pregnancy and in women of child bearing potential.

Description

This session will review the cardiovascular risk factors in psoriasis and the impact of treatment. There will also be an overview on available biologics and how to best select the most appropriate biologic for each patient. There will be a lively debate on the use of oral agents as first line therapy. Managing nail psoriasis, genital psoriasis and psoriasis in women of child bearing potential will also be emphasized. There will also be discussion on management of psoriatic arthritis. The link between depression and psoriasis will be discussed. Is depression a comorbidity or a side effect? This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Blauvelt, Andrew, MD: AbbVie – A(H), C(H), I(Fees); Aclaris Therapeutics Inc. – A(H), C(H), I(Fees); Allergan, Inc – I(Fees); Almirall – A(H), C(H); Amgen – A(H), C(H), I(Fees); Boehringer Ingelheim – A(H), C(H), I(Fees); Celgene – I(Fees); Dermavant Sciences – I(Fees); Dermira – A(H), C(H), I(Fees); Eli Lilly and Company – A(H), C(H), I(Fees), SP(H); Genentech, Inc. – I(Fees); GlaxoSmithKline – I(Fees); Janssen-Ortho Inc. – A(H), C(H), I(Fees), SP(H); Leo Pharma Inc – A(H), C(H), I(Fees); Merck & Co., Inc – A(H), C(H), I(Fees); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Fees); Pfizer Inc. – I(Fees); Regeneron – A(H), C(H), I(Fees), SP(H); Sandoz, a Novartis company – A(H), C(H), I(Fees); Sanofi – A(H), C(H), SP(H); Sienna Biopharmaceuticals – A(H), C(H), I(Fees); Sun Pharmaceutical Industries Ltd. – A(H), C(H); UCB – A(H), C(H), I(Fees); Valeant Pharmaceuticals International – A(H), C(H), I(Fees); Vidac Pharma – A(H), C(H), I(Fees);
  • Elewski, Boni E., MD: AbbVie – I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Celgene Corporation – C(H), I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – A(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H); Merck & Co., Inc – I(Grants/Research Funding); Novan – C(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Gelfand, Joel M., MD, MSCE: AbbVie – I(Grants/Research Funding); BMS – C(Fees); Boehringer Ingelheim – C(H); Celgene Corporation – I(Grants/Research Funding); Dr. Reddy – C(H); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Regeneron – C(H); Sanofi – I(Grants/Research Funding); Sanofi US Services – A(H); Society for Investigative Dermatology – O(H); UCB – O(Fees);
  • Gordon, Kenneth B., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Demira – C(H); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Lilly ICOS LLC – A(H); Merck & Co., Inc. – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H);
  • Kimball, Alexandra Boer, MD, MPH: AbbVie – C(H), I(Grants/Research Funding); Dermira – C(H); Escalier Biosciences – A(H), A(OB); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Residency/Fellowship Program Funding); Lilly ICOS LLC – C(H); Merck & Co., Inc – C(H); New Enterprise Associates – C(H); Novartis – C(H); Procter & Gamble Company – C(H); Purdue Pharma – C(H); Regeneron – C(H); Sanofi/Regeneron – C(H); UCB – C(H);
  • Langley, Richard G. B., MD: AbbVie – A(H), I(Grants/Research Funding), SP(H); Amgen – I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – A(H); Centocor Ortho Biotech Inc. – A(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), I(H); Genentech, Inc. – I(Grants/Research Funding); Isotechnika Pharma Inc. – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Merck Serono – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding), SP(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding);
  • Menter, Alan, MD: AbbVie – A(H), C(H), I(Grants/Research Funding), SP(H); Afecta Pharmaceuticals – A(NC), C(NC); Amgen – A(Grants/Research Funding), C(H), I(Grants/Research Funding), SP(H); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding), I(H); Galderma USA – C(H); Janssen Biotech – SP(H); Janssen Pharmaceuticals, Inc – A(H), C(H), I(Grants/Research Funding); LEO Pharma, US – A(H), C(H), SP(H); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Medscape – A(H); Menlo Therapeutics – C(H); Merck & Co., Inc – I(Grants/Research Funding); New Enterprise Associates – C(Fees); Novartis – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding), SP(H); Prime Education – Independent Contractor(Fees); Promius Pharma, LLC – C(Fees), SP(H); Sienna Biopharmaceuticals – C(H); Spherix Global Insights US, Inc. – C(Fees); Valeant Pharmaceuticals North America LLC – C(Fees); Wyeth Labs – C(H), SP(H);
  • Wu, Jashin J., MD: AbbVie – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding);
Schedule
Saturday, February 17
9:00 AM
Dr. Elewski / Welcome and Introduction
9:03 AM
Dr. Lebwohl / Overview of biologics for Psoriasis: How to select the best drug for your patient.
9:27 AM
Dr. Gelfand / Cardiovascular risk in Psoriasis: Implications for your clinical practice
9:50 AM
Dr. Gordon / Debate: Use oral medications before biologics
10:00 AM
Dr. Langley / Debate: Biologics should be used first line
10:10 AM
All faculty / Debate and Rebuttal: “Should we bypass oral medications and go direct to biologics in patients with moderate to severe psoriasis?”
10:20 AM
Dr. Menter / Treatment of genital Psoriasis
10:35 AM
Dr. Elewski / Treatment of nail Psoriasis
10:50 AM
Dr. Wu / Depression and Psoriasis: Is this a comorbidity or side effect?
11:05 AM
Dr. Blauvelt / Should TNF blockers still be first line in patients with PSA and PSO?
11:25 AM
Dr. Kimball / Treatment of Psoriasis in pregnancy
11:45 AM
All faculty / Panel
12:00 PM
/ End
Event Details
  • Date
    Saturday, February 17
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 30B
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
Speakers
  • Alan Menter, MD, FAAD - Handout
  • Alexandra Boer Kimball, MD, MPH, FAAD
  • Andrew Blauvelt, MD, FAAD
  • Jashin J. Wu, MD, FAAD
  • Joel M. Gelfand, MD, MSCE, FAAD - Handout
  • Kenneth B. Gordon, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Richard G. B. Langley, MD, FAAD